Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin's Anti-Anhedonic Effects in Depression
NCT07490353Phase 1Recruiting
- Sponsor
- Medical University of Vienna
- Start
- Nov 2025
- Primary completion
- May 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of psilocybin in major depressive disorder (MDD) and anhedonia ((none)) (2 arms), sponsored by Medical University of Vienna. Primary endpoints: Aesthetic task up to 9 weeks, Monetary Incentive Delay Task up to 8 weeks and 14 more. Started Nov 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)anhedonia ((none))
Beyond the preview
Go deeper on NCT07490353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490353.